In a report released today, Brian Cheng from J.P. Morgan reiterated a Buy rating on PTC Therapeutics, with a price target of $68.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brian Cheng’s rating is based on several compelling factors that highlight PTC Therapeutics’ potential for growth. The company has successfully shifted its focus from Duchenne Muscular Dystrophy (DMD) to Phenylketonuria (PKU), with the launch of Sephience being a significant milestone. This transition is supported by a robust cash reserve exceeding $2 billion and strategic partnerships in Spinal Muscular Atrophy (SMA) and Huntington’s Disease (HD), which provide a strong foundation for valuation.
Moreover, the upcoming PDUFA decision for vatiquinone is seen as a pivotal event that could eliminate regulatory uncertainties and refocus investor attention on Sephience’s promising launch. The demand for Sephience is expected to be strong, driven by its efficacy and safety advantages over existing treatments. Additionally, the company’s diversified portfolio, including potential upsides from vatiquinone and Translarna, further strengthens its growth prospects. These elements, combined with a solid financial position, underpin Cheng’s Buy rating and the December 2025 price target of $68.
In another report released on July 30, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $55.00 price target.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.